S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
NASDAQ:CVRX

CVRx Stock Forecast, Price & News

$17.05
+0.14 (+0.83 %)
(As of 10/28/2021 11:00 AM ET)
Add
Compare
Today's Range
$17.00
$17.17
50-Day Range
$14.65
$20.70
52-Week Range
$14.00
$29.00
Volume
74 shs
Average Volume
131,020 shs
Market Capitalization
$346.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CVRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter.


CVRx logo

About CVRx

CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CVRX
Phone
N/A
Employees
63
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$346.90 million
Next Earnings Date
11/4/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

124th out of 1,372 stocks

Surgical & Medical Instruments Industry

14th out of 125 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












CVRx (NASDAQ:CVRX) Frequently Asked Questions

Is CVRx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CVRx stock.
View analyst ratings for CVRx
or view top-rated stocks.

What stocks does MarketBeat like better than CVRx?

Wall Street analysts have given CVRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CVRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CVRx?

CVRx saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 628,200 shares, a decrease of 46.3% from the September 30th total of 1,170,000 shares. Based on an average trading volume of 116,700 shares, the short-interest ratio is presently 5.4 days. Currently, 7.8% of the shares of the stock are sold short.
View CVRx's Short Interest
.

When is CVRx's next earnings date?

CVRx is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for CVRx
.

How can I listen to CVRx's earnings call?

CVRx will be holding an earnings conference call on Thursday, November 4th at 5:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were CVRx's earnings last quarter?

CVRx, Inc. (NASDAQ:CVRX) issued its earnings results on Wednesday, August, 4th. The company reported ($48.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($21.27) by $27.21. The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $2.77 million.
View CVRx's earnings history
.

What guidance has CVRx issued on next quarter's earnings?

CVRx updated its third quarter 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.30 million-$3.60 million.

What price target have analysts set for CVRX?

4 Wall Street analysts have issued 12 month price objectives for CVRx's stock. Their forecasts range from $20.22 to $30.00. On average, they anticipate CVRx's share price to reach $25.06 in the next twelve months. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for CVRx
or view top-rated stocks among Wall Street analysts.

Who are CVRx's key executives?

CVRx's management team includes the following people:
  • Mr. Nadim Yared, CEO, Pres & Director (Age 53, Pay $661.88k)
  • Mr. John R. Brintnall, Chief Strategy Officer & Sec. (Age 68, Pay $390.42k)
  • Mr. Jared Oasheim, Chief Financial Officer (Age 38)
  • Mr. Paul Verrastro, Chief Marketing Officer (Age 58)

When did CVRx IPO?

(CVRX) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

What is CVRx's stock symbol?

CVRx trades on the NASDAQ under the ticker symbol "CVRX."

When does CVRx's lock-up period expire?

CVRx's lock-up period expires on Monday, December 27th. CVRx had issued 7,000,000 shares in its public offering on June 30th. The total size of the offering was $126,000,000 based on an initial share price of $18.00. After the expiration of CVRx's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are CVRx's major shareholders?

CVRx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Strs Ohio (0.01%). Company insiders that own CVRx stock include Mudit K Jain and Nea Partners 10 L P.
View institutional ownership trends for CVRx
.

Which institutional investors are buying CVRx stock?

CVRX stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought CVRx stock in the last two years include Mudit K Jain, and Nea Partners 10 L P.
View insider buying and selling activity for CVRx
or or view top insider-buying stocks.

How do I buy shares of CVRx?

Shares of CVRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CVRx's stock price today?

One share of CVRX stock can currently be purchased for approximately $17.05.

How much money does CVRx make?

CVRx has a market capitalization of $346.90 million.

How many employees does CVRx have?

CVRx employs 63 workers across the globe.

What is CVRx's official website?

The official website for CVRx is www.cvrx.com.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.